Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Michael J MinzenbergCameron S Carter

Abstract

Control-related cognitive processes such as rule selection and maintenance are associated with cortical oscillations in the gamma range, and modulated by catecholamine neurotransmission. Control-related gamma power is impaired in schizophrenia, and an understudied treatment target. It remains unknown whether pro-catecholamine pharmacological agents augment control-related gamma oscillations in schizophrenia. We tested the effects of 4-week fixed-dose daily adjunctive modafinil (MOD) 200 mg, in a randomized double-blind, placebo-controlled, parallel-groups design. Twenty-seven stable schizophrenia patients performed a cognitive control task during EEG, at baseline and after 4 weeks of treatment. EEG data underwent time-frequency decomposition with Morlet wavelets to determine power of 4-80 Hz oscillations. The modafinil group (n=14), relative to placebo group (n=13), exhibited enhanced oscillatory power associated with high-control rule selection in the gamma range after treatment, with additional effects during rule maintenance in gamma and sub-gamma ranges. MOD-treated patients who exhibited improved task performance with treatment also showed greater treatment-related delay period gamma compared with MOD-treated patients with...Continue Reading

References

Nov 1, 1992·Neuroscience·D Pinault, M Deschênes
Nov 1, 1995·Neural Computation·A J Bell, T J Sejnowski
Dec 29, 2000·Nature Neuroscience·D DurstewitzT J Sejnowski
Mar 17, 2001·Nature Reviews. Neuroscience·E K Miller
Oct 13, 2001·The Neuroscientist : a Review Journal Bringing Neurobiology, Neurology and Psychiatry·E Salinas, T J Sejnowski
Jan 23, 2003·Clinical Pharmacokinetics·Philmore Robertson, Edward T Hellriegel
Apr 27, 2004·Neuroreport·L Elliot HongRobert W Buchanan
Apr 27, 2005·Cognitive, Affective & Behavioral Neuroscience·Silvia A Bunge
Jul 19, 2005·Annual Review of Neuroscience·Gary Aston-Jones, Jonathan D Cohen
Sep 6, 2005·Trends in Neurosciences·Alberto BacciDavid A Prince
Dec 7, 2005·The American Journal of Psychiatry·Jonathan K WynnMichael F Green
Jun 6, 2006·Cerebral Cortex·Tamer DemiralpHüseyin Beydagi
Aug 4, 2006·The Journal of Pharmacology and Experimental Therapeutics·Bertha K MadrasAlan J Fischman
Oct 13, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Kafui DzirasaMiguel A L Nicolelis
Oct 31, 2006·Progress in Brain Research·Julie Onton, Scott Makeig
Dec 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·R Y ChoC S Carter
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael J Minzenberg, Cameron S Carter
Sep 14, 2007·Annals of Medicine·Keith Q Tanis, Ronald S Duman
Dec 18, 2007·Biological Psychiatry·Kevin M SpencerRobert W McCarley
Apr 11, 2008·Biological Psychiatry·Kevin M SpencerRobert W McCarley
Oct 17, 2008·The American Journal of Psychiatry·David A LewisDebra Montrose
Nov 26, 2008·The Journal of Clinical Psychiatry·Carlos Saavedra-VelezJean-Pierre Lindenmayer
Mar 19, 2009·JAMA : the Journal of the American Medical Association·Nora D VolkowKaren Apelskog-Torres
Aug 5, 2009·Archives of General Psychiatry·Michael J MinzenbergDavid C Glahn
Oct 17, 2009·NeuroImage·Brenton W McMenaminRichard J Davidson
Nov 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L Elliot HongAdrienne C Lahti
Sep 10, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael J MinzenbergCameron S Carter
Sep 17, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Tyler A LeshCameron S Carter
Feb 24, 2011·Experimental and Clinical Psychopharmacology·Michael J Minzenberg, Jong H Yoon
Dec 20, 2011·Trends in Cognitive Sciences·Michael J Minzenberg, Cameron S Carter
Mar 1, 2012·Biological Psychiatry·Kenji KiriharaGregory A Light
Mar 24, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Matthew A AlbrechtMathew T Martin-Iverson
Jun 22, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Michael J Minzenberg

❮ Previous
Next ❯

Citations

Oct 18, 2016·Genes, Brain, and Behavior·N W Gilpin, J L Weiner
Feb 2, 2018·Journal of Clinical and Experimental Neuropsychology·Rachel P SoChi-Ming A Chen
Feb 23, 2020·Journal of Cognitive Neuroscience·Orly RubinstenTamar Furman
Dec 13, 2019·The Cochrane Database of Systematic Reviews·Javier Ortiz-OrendainLuis Enrique Colunga-Lozano
Apr 17, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Szilvia VasA Jennifer Morton
Jul 28, 2020·Frontiers in Systems Neuroscience·Inga Griskova-BulanovaJovana Bjekic
Jun 27, 2020·Frontiers in Psychiatry·Sokichi HondaTakuma Mihara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Michael J MinzenbergCameron S Carter
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Michael J MinzenbergCameron S Carter
© 2021 Meta ULC. All rights reserved